New cancer drug cocktail aims to shrink tough tumors
NCT ID NCT04840589
Summary
This early-phase trial is testing the safety and best dose of a new oral drug, ZEN003694, when given with standard immunotherapy drugs (nivolumab with or without ipilimumab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if this combination can help the immune system fight the cancer and shrink or stabilize tumors. The study is currently suspended and was enrolling about 66 adults with specific types of recurrent or metastatic cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.